摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-[[5-[[2-Butyl-4-(2-methylphenyl)-5-oxopiperazin-1-yl]methyl]imidazol-1-yl]methyl]benzonitrile

中文名称
——
中文别名
——
英文名称
4-[[5-[[2-Butyl-4-(2-methylphenyl)-5-oxopiperazin-1-yl]methyl]imidazol-1-yl]methyl]benzonitrile
英文别名
——
4-[[5-[[2-Butyl-4-(2-methylphenyl)-5-oxopiperazin-1-yl]methyl]imidazol-1-yl]methyl]benzonitrile化学式
CAS
——
化学式
C27H31N5O
mdl
——
分子量
441.6
InChiKey
JMIHNUBSAWPDID-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.3
  • 重原子数:
    33
  • 可旋转键数:
    8
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.37
  • 拓扑面积:
    65.2
  • 氢给体数:
    0
  • 氢受体数:
    4

文献信息

  • Active salt forms with tyrosine kinase activity
    申请人:——
    公开号:US20040023978A1
    公开(公告)日:2004-02-05
    The present invention relates to orally active salt forms of the mesylate salt of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, retinal ischemia, macular edema, inflammatory diseases, and the like in mammals.
    本发明涉及口服活性盐形式的甲磺酸盐,其抑制、调节和/或调控酪氨酸激酶信号传导的4-[2-(5-氰基噻唑-2-基基)-吡啶-4-基甲基]-哌嗪-1-羧酸甲酰胺,含有这些化合物的组合物,以及使用它们治疗酪氨酸激酶依赖性疾病和症状的方法,如血管生成、癌症、肿瘤生长、动脉粥样硬化、老年性黄斑变性、糖尿病视网膜病变、视网膜缺血、黄斑肿、炎症性疾病等哺乳动物。
  • Polymorphs with tyrosine kinase activity
    申请人:——
    公开号:US20040023980A1
    公开(公告)日:2004-02-05
    The present invention relates to active polymorphs of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angio-genesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, retinal ischemia, macular edema, inflammatory diseases, and the like in mammals.
    本发明涉及活性多型体4-[2-(5-氰基噻唑-2-基基)-吡啶-4-基甲基]-哌嗪-1-羧酸甲酰胺,其抑制、调节和/或调控酪氨酸激酶信号传导,含有这些化合物的组合物,以及使用它们治疗酪氨酸激酶依赖性疾病和症状的方法,如血管生成、癌症、肿瘤生长、动脉粥样硬化、老年性黄斑变性、糖尿病视网膜病变、视网膜缺血、黄斑肿、炎症性疾病等在哺乳动物中。
  • Method of treating cancer
    申请人:——
    公开号:US20030220241A1
    公开(公告)日:2003-11-27
    The present invention relates to methods of treating cancer using a combination of a compound which is a PSA conjugate and a compound which is a inhibitor of prenyl-protein transferase, which methods comprise administering to said mammal, either sequentially in any order or simultaneously, amounts of at least two therapeutic agents selected from a group consisting of a compound which is a PSA conjugate and a compound which is a inhibitor of prenyl-protein transferase. The invention also relates to methods of preparing such compositions.
    本发明涉及使用一种PSA共轭物和一种前脂蛋白转移酶抑制剂的组合治疗癌症的方法,该方法包括向所述哺乳动物施用来自以下组中选择的至少两种治疗剂的量,所述组包括一种PSA共轭物和一种前脂蛋白转移酶抑制剂,所述治疗剂可以顺序给药或同时给药。该发明还涉及制备这种组合物的方法。
  • Salt forms with tyrosine kinase activity
    申请人:——
    公开号:US20040023981A1
    公开(公告)日:2004-02-05
    The present invention relates to salt forms of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angio-genesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, retinal ischemia, macular edema, inflammatory diseases, and the like in mammals.
    本发明涉及盐形式的4-[2-(5-氰基噻唑-2-基基)-吡啶-4-基甲基]-哌嗪-1-羧酸甲酰胺,该盐形式抑制、调节和/或调控酪氨酸激酶信号转导,含有这些化合物的组合物,以及使用它们治疗酪氨酸激酶依赖性疾病和症状的方法,如血管生成、癌症、肿瘤生长、动脉粥样硬化、老年性黄斑变性、糖尿病视网膜病变、视网膜缺血、黄斑肿、炎症性疾病等哺乳动物。
  • Tyrosine kinase inhibitors
    申请人:——
    公开号:US20020137755A1
    公开(公告)日:2002-09-26
    The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    本发明涉及抑制、调节和/或调控酪氨酸激酶信号传导的化合物,含有这些化合物的组合物,以及使用它们治疗依赖于酪氨酸激酶的疾病和病况的方法,如在哺乳动物中的血管生成、癌症、肿瘤生长、动脉粥样硬化、老年性黄斑变性、糖尿病视网膜病变、炎症性疾病等。
查看更多